Table 2.
Characteristics of 389 uPROPHET patients by OSTEO18 categories (starts).
| Characteristic | OSTEO18 score |
p-value | |||
|---|---|---|---|---|---|
| < −1 | -1–0 | 0–1 | ≥1 | ||
| Number in group, n (%) | 93 (23.9) | 107 (27.5) | 97 (24.9) | 92 (23.7) | |
| Time after HTx (years) | 4.33 (1.26, 13.2) | 6.26 (1.52, 11.2) | 7.53 (1.74, 15.6) | 10.2 (3.87, 16.1) | 0.0024 |
| Age (years) | 54.0 (13.5) | 55.3 (15.4) | 57.1 (14.2) | 62.5 (12.2) | <0.0001 |
| BMI (kg/m2) | 25.7 (4.12) | 25.3 (4.50) | 24.4 (4.24) | 25.8 (4.04) | 0.78 |
| SBP (mm Hg) | 142.3 (18.8) | 141.2 (20.7) | 141.7 (21.8) | 144.3 (21.6) | 0.50 |
| DBP (mm Hg) | 86.4 (11.2) | 85.0 (12.1) | 84.4 (11.5) | 86.6 (10.9) | >0.99 |
| Serum creatinine (μmol/L) | 118.4 (35.9) | 121.0 (45.8) | 126.7 (45.0) | 135.0 (47.6) | 0.0062 |
| eGFR (ml/min/1.73 m [2]) | 63.7 (24.2) | 63.6 (26.2) | 58.3 (25.3) | 51.6 (20.1) | 0.0002 |
| Serum albumin (g/L) | 43.9 (3.06) | 44.2 (3.36) | 44.0 (3.03) | 43.0 (3.47) | 0.084 |
| Total serum calcium (mmol/L) | 2.38 (0.11) | 2.38 (0.12) | 2.40 (0.11) | 2.40 (0.12) | 0.16 |
| Ionized serum calcium (mmol/L) | 2.46 (0.15) | 2.46 (0.17) | 2.48 (0.14) | 2.46 (0.17) | 0.76 |
| Sex | |||||
| Men, n (%) | 73 (78.5) | 81 (75.7) | 70 (72.2) | 70 (76.1) | 0.58 |
| Women, n (%) | 20 (21.5) | 26 (24.3) | 27 (27.8) | 22 (23.9) | |
| Indication for HTx | |||||
| Ischemic cardiomyopathy, n (%) | 34 (36.6) | 38 (35.5) | 34 (35.1) | 44 (47.8) | 0.14 |
| Dilated cardiomyopathy, n (%) | 38 (40.9) | 45 (42.1) | 40 (41.2) | 34 (37.0) | 0.58 |
| Other, n (%) | 21 (22.6) | 23 (21.5) | 23 (23.7) | 14 (15.2) | 0.30 |
| Past smoker, n (%) | 58 (63.0) | 61 (57.0) | 61 (63.5) | 59 (64.8) | 0.58 |
| Hypertension, n (%) | 79 (84.9) | 95 (88.8) | 88 (90.7) | 86 (93.5) | 0.056 |
| Diabetes, n (%) | 22 (23.7) | 23 (21.5) | 22 (22.7) | 23 (25.0) | 0.78 |
| Osteoporotic fracture, n (%) | 1 (1.1) | 2 (1.9) | 2 (2.1) | 7 (7.6) | 0.021 |
| BMD T-score ≤ -2.5, n (%) | 10 (10.8) | 11 (10.3) | 17 (17.5) | 18 (19.6) | 0.037 |
| Anti-osteoporotic treatment, n (%) | 11 (11.8) | 21 (19.6) | 39 (40.2) | 52 (56.5) | <0.0001 |
| Thiazides, n (%) | 10 (10.8) | 6 (5.6) | 14 (14.4) | 12 (13.0) | 0.25 |
| Immunosuppression | |||||
| Tacrolimus, n (%) | 77 (82.8) | 86 (80.4) | 66 (68.0) | 50 (54.3) | <0.0001 |
| Cyclosporine, n (%) | 12 (12.9) | 10 (9.3) | 22 (22.7) | 32 (34.8) | <0.0001 |
| Everolimus, n (%) | 5 (5.4) | 8 (7.5) | 4 (4.1) | 4 (4.3) | 0.52 |
| Mycophenolic acid, n (%) | 65 (69.9) | 82 (76.6) | 70 (72.2) | 64 (69.6) | 0.77 |
| Azathioprine, n (%) | 9 (9.7) | 4 (3.7) | 9 (9.3) | 4 (4.3) | 0.40 |
| Methylprednisolone, n (%) e | 28 (30.1) | 36 (33.6) | 33 (34.0) | 37 (40.2) | 0.17 |
Values are mean (SD), median (IQR) or number of patients (%). Abbreviations: HTx, heart transplantation; BMI, body mass index; SBP/DBP, systolic/diastolic blood pressure; eGFR, estimated glomerular filtration rate; BMD, bone mineral density. Anti-osteoporotic treatment refers to calcium supplementation, vitamin D supplements and/or bisphosphonates. To convert serum creatinine from μmol/L to mg/dL, multiply by 0.0113. To convert serum albumin from g/L to g/dL, multiply by 0.1. To convert serum total and ionized calcium from mmol/L to mg/dL, multiply by 4. p-values refer to the difference between cases and controls in the derivation, replication and time-shifted replication datasets.